---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-23-000054"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T05:00:26.231436+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics Q2 net loss $12.1M; cash $282.8M; Advance-HTN enrollment on track

## Summary
- Net loss of $12.1M for Q2 2023 vs $6.5M in Q2 2022, driven by increased R&D and G&A spend.
- Cash, equivalents and investments $282.8M as of June 30, 2023, up from $110.1M at Dec 31, 2022.
- R&D expenses $11.9M vs $5.6M YoY, reflecting initiation of lorundrostat pivotal program.
- Advance-HTN Phase 2 trial enrollment ongoing; topline data expected 1H 2024.
- Phase 3 Launch-HTN trial and Phase 2 CKD trial both expected to start in 2H 2023.

## SEC filing metadata
- accession: 0001933414-23-000054
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/0001933414-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/mlys-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-23-000054
- JSON: https://secwatch.observer/filing/0001933414-23-000054.json
- Plain text: https://secwatch.observer/filing/0001933414-23-000054.txt

## Key facts
- Earnings Releases
  Mineralys Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $12.1 million for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $12.1 million for the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/0001933414-23-000054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.